Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction

Transplant Infectious Disease

Volumn 11, Issue 5, 2009, Pages 393-399

  Omar, H ^a,b   Hagglund H ^a,b   Gustafsson Jernberg, A ^b   Leblanc, K ^a,b   Mattsson, J ^a,b   Remberger, M ^a,b   Ringden O ^a,b   Sparrelid, E ^b   Sundin, M ^a,b   Winiarski, J ^b   Yun, Z ^b   Ljungman, P ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epstein Barr virus; Post transplant lymphoproliferative disease; Stem cell transplantation

Indexed keywords

CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; RITUXIMAB; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD DONOR; CHILD; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DNA DETERMINATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS ASSOCIATED POST TRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFANT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SPLENECTOMY; STEM CELL TRANSPLANTATION; VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK FACTORS; STEM CELL TRANSPLANTATION; VIRAL LOAD; YOUNG ADULT;

EID: 70349663887     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00410.x     Document Type: Article

References (41)

1. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998 339 (17) : 1186 1193.
2. Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008 40 (1) : 68 70.
3. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005 56 : 29 44.
4. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007 7 (2) : 96 101.
5. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999 94 (7) : 2208 2216.
6. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006 108 (8) : 2874 2880.
7. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998 91 (8) : 3079 3083.
8. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006 91 (8) : 1059 1067.
9. Gaeta A, Nazzari C, Verzaro S, et al. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients. New Microbiol 2006 29 (4) : 231 241.
10. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007 39 (3) : 235 244.
11. Gartner BC, Schafer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002 40 (2) : 351 358.
12. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004 103 (10) : 3979 3981.
13. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002 99 (12) : 4364 4369.
14. Merlino C, Cavallo R, Bergallo M, et al. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients. New Microbiol 2003 26 (2) : 141 149.
15. Styczynski J, Wysocki M, Dluzniewska A, et al. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. Anticancer Res 2008 28 (3B) : 1927 1931.
16. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007 41 (11) : 1850 1858.
17. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002 8 (12) : 674 682. (Pubitemid 36097807)
18. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004 78 (7) : 1014 1020. (Pubitemid 39391863)
19. Norlin AC, Sairafi D, Mattsson J, Ljungman P, Ringden O, Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 2008 41 (3) : 267 273.
20. Ringden O, Pihlstedt P, Markling L, et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991 7 (3) : 221 226.
21. Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999 24 (8) : 823 830.
22. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000 38 (2) : 712 715.
23. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006 91 (1) : 78 83.
24. Robin M, Marque-Juillet S, Scieux C, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007 92 (9) : 1254 1257. (Pubitemid 350144187)
25. Meerbach A, Wutzler P, Hafer R, Zintl F, Gruhn B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 2008 80 (3) : 441 454.
26. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2008 Dec 1 [Epub ahead of print].
27. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001 98 (4) : 972 978.
28. Annels NE, Kalpoe JS, Bredius RG, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006 42 (12) : 1743 1748.
29. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005 80 (12) : 1692 1698.
30. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006 107 (8) : 3053 3057.
31. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005 5 (12) : 2901 2906.
32. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000 95 (3) : 807 814.
33. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995 345 (8941) : 9 13.
34. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007 110 (4) : 1123 1131.
35. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post tarnsplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008 42 (3) : 181 186.
36. Gaudin E, Rosado M, Agenes F, McLean A, Freitas AA. B-cell homeostasis, competition, resources, and positive selection by self-antigens. Immunol Rev 2004 197 : 102 115.
37. Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003 32 (1) : 97 102.
38. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988 71 (5) : 1234 1243.
39. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996 87 (9) : 3633 3639.
40. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003 21 (7) : 1352 1358.
41. Lange A, Klimczak A, Dlubek D, Dybko J. B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. Transplant Proc 2003 35 (8) : 3093 3095.